Mineralys Therapeutics, Inc. MLYS
We take great care to ensure that the data presented and summarized in this overview for Mineralys Therapeutics, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in MLYS
Top Purchases
Top Sells
About MLYS
Insider Transactions at MLYS
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|
Apr 14
2025
|
David Malcom Rodman Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
11,366
-4.7%
|
$159,124
$14.26 P/Share
|
|
Apr 14
2025
|
David Malcom Rodman Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,348
+4.91%
|
$6,348
$1.08 P/Share
|
|
Apr 11
2025
|
Adam Scott Levy CFO and Secretary |
SELL
Open market or private sale
|
Direct |
10,757
-4.76%
|
$129,084
$12.06 P/Share
|
|
Apr 11
2025
|
Jon Congleton Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
15,319
-1.75%
|
$183,828
$12.19 P/Share
|
|
Apr 01
2025
|
David Malcom Rodman Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
55,771
-11.93%
|
$836,565
$15.93 P/Share
|
|
Apr 01
2025
|
David Malcom Rodman Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,606
+0.92%
|
$1,606
$1.08 P/Share
|
|
Mar 13
2025
|
Samsara Bio Capital Gp, LLC |
BUY
Open market or private purchase
|
Indirect |
600,000
+9.56%
|
$7,800,000
$13.5 P/Share
|
|
Mar 13
2025
|
Srinivas Akkaraju |
BUY
Open market or private purchase
|
Indirect |
600,000
+9.56%
|
$7,800,000
$13.5 P/Share
|
|
Mar 13
2025
|
Ra Capital Management, L.P. |
BUY
Open market or private purchase
|
Indirect |
1,296,296
+23.25%
|
$16,851,848
$13.5 P/Share
|
|
Mar 12
2025
|
David Malcom Rodman Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,349
+3.58%
|
$6,349
$1.08 P/Share
|
|
Feb 12
2025
|
David Malcom Rodman Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,348
+3.72%
|
$6,348
$1.08 P/Share
|
|
Jan 13
2025
|
Jon Congleton Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
18,333
-2.05%
|
$164,997
$9.06 P/Share
|
|
Jan 13
2025
|
David Malcom Rodman Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
11,367
+3.53%
|
$0
$0.81 P/Share
|
|
Jan 13
2025
|
Adam Scott Levy CFO and Secretary |
SELL
Open market or private sale
|
Direct |
10,757
-2.27%
|
$96,813
$9.36 P/Share
|
|
Dec 11
2024
|
David Malcom Rodman Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,017
+3.32%
|
$0
$0.54 P/Share
|
|
Nov 11
2024
|
David Malcom Rodman Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
5,026
-3.44%
|
$75,390
$15.0 P/Share
|
|
Nov 11
2024
|
David Malcom Rodman Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,043
+3.38%
|
$0
$0.81 P/Share
|
|
Nov 06
2024
|
David Malcom Rodman Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
25,482
-15.78%
|
$382,230
$15.03 P/Share
|
|
Nov 06
2024
|
David Malcom Rodman Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
25,482
+13.63%
|
$25,482
$1.08 P/Share
|
|
Oct 14
2024
|
David Malcom Rodman Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,352
+3.79%
|
$5,352
$1.08 P/Share
|
Last 12 Months Summary
Buy / Acquisition
2.64M
Shares
From
4
Insiders
| Open market or private purchase | 2.5M shares |
|---|---|
| Exercise of conversion of derivative security | 140K shares |
Sell / Disposition
975K
Shares
From
4
Insiders
| Open market or private sale | 975K shares |
|---|